SUMMARY A randomised clinical trial was carried out to explore the efficacy of single dose tetracycline therapy in cholera. One hundred and eighteen adult patients were assigned to receive either tetracycline in a single 1 g, or a single 2 g dose, or tetracycline 500 mg every six hours four times, or no antibiotics as controls. The means of total liquid stool volumes after treatment were lower in the single 1 g dose group (168-0±20-9 ml/kg), in single 2 g dose group (229.5±45.6 ml/kg), and multiple dose group (214±28.5 ml/kg), than in the control group (499-1±56-5 ml/kg) (p<0.05). Similarly, the means of durations of diarrhoea and intravenous fluid requirements were significantly lower in the single dose and multiple dose tetracycline groups, than in the controls (p<0-05). The mean durations of excretion of Vibrio cholerae were significantly shortened from 3*9±0-2 days in the control group to 1-9±0-2 days in single 1 g dose, to 2-2±0*4 days in single 2 g dose and 1-3±0X1 days in multiple dose groups, respectively (p<005). Three patients in the single 1 g dose group and two patients in single 2 g dose group had clinical relapses with excretion of V cholerae during the relapses, but this was not significantly more frequent than that in the multiple dose group (p>0-05). These findings suggest that although multiple dose tetracycline therapy remains the best choice, a single dose of either 1 g or 2 g tetracycline appears to be a reasonable alternative for the treatment of cholera as an adjunct to rehydration therapy.
Cholera is the severest of all forms of watery diarrhoeal diseases that may lead to dehydration and death. The effectiveness of tetracycline as an adjunct to rehydration therapy in the clinical management of acute cholera has been well documented. ' Intravenous fluid intake and stool, vomitus and urine output were carefully measured every eight hours until diarrhoea stopped. 'End of diarrhoea' was defined to have occurred at the end of the last eight hour period in which liquid stool was passed. If a patient passed soft or formed stool thereby reaching 'end of diarrhoea' and subsequently passed liquid stool, this was considered to be a clinical relapse.
Catheter specimens of stool or rectal swabs were obtained daily for culture of V cholerae7 until cultures became negative for three consecutive days. Bacteria from colonies typical of V cholerae were tested for agglutination with polyvalent 0 group specific antisera and were tested for haemagglutinating activity with chicken erythrocytes.
If a patient become bacteriologically negative for at least two consecutive days and was subsequently positive for V cholerae, this was considered to be bacteriological relapse.
After the end of the study, data of the four groups of patients were analysed by two tailed normal test (Z test), X2 and Fisher exact test.
Results
The 118 patients were comparable in mean age, sex distribution, clinical dehydration, body weight and duration of diarrhoea before admission ( Table 1) . The majority of patients in each group were infected with Ogawa serotype, classical biotype, of V cholerae. All 118 isolates of V cholerae were susceptible to tetracycline by in vitro testing.
Patients treated with single and multiple doses of tetracycline responded quickly with sharp reductions in stool outputs in nearly all patients by the second eight hour period after treatment. Measurements of stool volumes at 16 hourly intervals after treatment showed that all three groups receiving tetracycline produced significantly less stool than the controls at 32, 48, 64, and 80 hour after treatment (p<0)05, Figure) . The mean duration of diarrhoea of 35-2 h after single 1 g dose, 42.8 h after single 2 g dose and 37-4 h after multiple dose treatment were significantly less than the mean of 85.4 h for the controls (p<005) ( 
Discussion
Although emergence of multiply antibiotic resistant V cholerae has been reported in few cases in Bangladesh' and Tanzania,' tetracycline has remained the drug of choice in the treatment of cholera and it had been proved beyond doubt that it reduces gastrointestinal fluid loss, duration of diarrhoea and also eliminates V cholerae from stool within 48 hours. Using single dose antibiotic therapy the physician can ensure that the patient has taken his full course of therapy and does not have to depend on patient compliance. The efficacy of single large dose therapy in infections in probably related to the rapid attainment of high concentration of the drug at the Table 2 Duration ofdiarrhoea, outputofstool, intravenousfluid requirement, and vibrio excretion ofcholera patients treated with single dose tetracycline l g or2 g, multiple dose tetracycline 500mg every site of infections causing rapid destruction of the invading organisms. Our study has shown that single 1 g or 2 g dose tetracycline was as effective as multiple dose therapy when mean values of duration of diarrhoea, liquid stool output, intravenous fluid requirement, and excretion of V cholerae were compared. Although initial response is good, clinical relapses with excretion of V cholerae during the relapses occurred in three patients (6-6%) in the single 1 g dose group and two patients (8.7%) in the single 2 g dose group while no relapse occurred in the multiple dose group. This frequency of clinical relapse in the patients treated with single dose tetracycline was not statistically significant. Larger studies will be required to determine whether the single dose is as effective as the multiple dose when treating relapses.
The duration of excretion of Vibrio cholerae after single dose tetracycline therapy, however, is not as effectively shortened as with multiple dose tetracycline therapy. It is not yet clear whether these asymptomatic culture positive patients represent a significant public health risk to the community, as symptomatic cholera patients only represent a small fraction of the total number of people infected with and excreting Vibrio cholerae during an epidemic.
In a previous study it was shown that in clinical cholera, the duration of antibiotic therapy appeared to be more important than the amount given.2 In this study, we have also observed that merely increasing in the dose of tetracycline does not exhance its therapeutic efficacies.
The primary and life saving treatment for clinical cholera remains rehydration and maintenance of continuing losses by oral rehydration or intravenous fluid. Treatment of adult patients with single dose 1 g or 2 g tetracycline in addition to careful attention to rehydration should give satisfactory results especially where supervision of patients is minimal such as outpatient clinics and rehydration centres and when busy physicians can ensure that the patient has taken his full course of therapy and does not have to rely on patients compliance. Another advantage of single 1 g dose therapy is that only half the amount of tetracycline (1 g) is used compared with multiple dose therapy. Clinical relapses were observed, however, in 7% cases with single dose therapy. Therefore multiple dose therapy is preferable but single dose treatment might be used in emergencies or when patients with relapses have access to care. 
